GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » RepliCel Life Sciences Inc (OTCPK:REPCF) » Definitions » Cyclically Adjusted Price-to-FCF

RepliCel Life Sciences (RepliCel Life Sciences) Cyclically Adjusted Price-to-FCF : (As of May. 17, 2024)


View and export this data going back to 2004. Start your Free Trial

What is RepliCel Life Sciences Cyclically Adjusted Price-to-FCF?

Shiller PE for Stocks: The True Measure of Stock Valuation


RepliCel Life Sciences Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for RepliCel Life Sciences's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

RepliCel Life Sciences Cyclically Adjusted Price-to-FCF Chart

RepliCel Life Sciences Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

RepliCel Life Sciences Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of RepliCel Life Sciences's Cyclically Adjusted Price-to-FCF

For the Biotechnology subindustry, RepliCel Life Sciences's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


RepliCel Life Sciences's Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, RepliCel Life Sciences's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where RepliCel Life Sciences's Cyclically Adjusted Price-to-FCF falls into.



RepliCel Life Sciences Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

RepliCel Life Sciences's Cyclically Adjusted FCF per Share for the quarter that ended in Sep. 2023 is calculated as:

For example, RepliCel Life Sciences's adjusted Free Cash Flow per Share data for the three months ended in Sep. 2023 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Sep. 2023 (Change)*Current CPI (Sep. 2023)
=-0.002/125.2304*125.2304
=-0.002

Current CPI (Sep. 2023) = 125.2304.

RepliCel Life Sciences Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201312 -0.234 96.945 -0.302
201403 -0.199 98.604 -0.253
201406 -0.207 99.473 -0.261
201409 -0.173 99.394 -0.218
201412 -0.206 98.367 -0.262
201503 -0.150 99.789 -0.188
201506 -0.207 100.500 -0.258
201509 -0.144 100.421 -0.180
201512 -0.101 99.947 -0.127
201603 -0.047 101.054 -0.058
201606 -0.068 102.002 -0.083
201609 -0.013 101.765 -0.016
201612 -0.118 101.449 -0.146
201703 -0.084 102.634 -0.102
201706 -0.090 103.029 -0.109
201709 -0.023 103.345 -0.028
201712 -0.029 103.345 -0.035
201803 -0.013 105.004 -0.016
201806 -0.006 105.557 -0.007
201809 -0.001 105.636 -0.001
201812 0.032 105.399 0.038
201903 -0.035 106.979 -0.041
201906 -0.025 107.690 -0.029
201909 -0.010 107.611 -0.012
201912 -0.007 107.769 -0.008
202003 -0.001 107.927 -0.001
202006 -0.002 108.401 -0.002
202009 -0.022 108.164 -0.025
202012 0.009 108.559 0.010
202103 -0.014 110.298 -0.016
202106 -0.047 111.720 -0.053
202109 0.010 112.905 0.011
202112 -0.014 113.774 -0.015
202203 -0.008 117.646 -0.009
202206 -0.010 120.806 -0.010
202209 -0.008 120.648 -0.008
202212 -0.004 120.964 -0.004
202303 -0.016 122.702 -0.016
202306 -0.005 124.203 -0.005
202309 -0.002 125.230 -0.002

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


RepliCel Life Sciences  (OTCPK:REPCF) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


RepliCel Life Sciences Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of RepliCel Life Sciences's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


RepliCel Life Sciences (RepliCel Life Sciences) Business Description

Traded in Other Exchanges
Address
570 Granville Street, Suite 900, Vancouver, BC, CAN, V6C 3P1
RepliCel Life Sciences Inc is a Canadian regenerative medicine company. It focuses on developing autologous cell therapies that treat functional cellular deficits. The company addresses various diseases such as chronic tendon injuries, androgenetic alopecia, and skin aging. Its development program of the company is based on distinct technology that utilizes cells isolated from a patient's healthy hair follicles. Also, the company develops a programmable cell injector device designed for dermal injections of cells, dermal filler products, and a variety of other products injected through the skin. The treatments delivered by the company use autologous cell therapy which is developed for the treatment of androgenetic alopecia. The revenue is generated from Licensing fees.